- Home
- PRQR vs BNTC Comparison
PRQR vs BNTC Comparison
Compare PRQR & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRQR
- BNTC
- Stock Information
- Founded
- PRQR 2012
- BNTC 1995
- Country
- PRQR Netherlands
- BNTC United States
- Employees
- PRQR N/A
- BNTC N/A
- Industry
- PRQR Biotechnology: Pharmaceutical Preparations
- BNTC Biotechnology: Pharmaceutical Preparations
- Sector
- PRQR Health Care
- BNTC Health Care
- Exchange
- PRQR Nasdaq
- BNTC Nasdaq
- Market Cap
- PRQR 309.5M
- BNTC 352.5M
- IPO Year
- PRQR 2014
- BNTC N/A
- Fundamental
- Price
- PRQR $1.72
- BNTC $13.67
- Analyst Decision
- PRQR Strong Buy
- BNTC Strong Buy
- Analyst Count
- PRQR 7
- BNTC 7
- Target Price
- PRQR $9.00
- BNTC $24.71
- AVG Volume (30 Days)
- PRQR 573.8K
- BNTC 33.9K
- Earning Date
- PRQR 05-08-2025
- BNTC 05-14-2025
- Dividend Yield
- PRQR N/A
- BNTC N/A
- EPS Growth
- PRQR N/A
- BNTC N/A
- EPS
- PRQR N/A
- BNTC N/A
- Revenue
- PRQR $21,212,711.00
- BNTC N/A
- Revenue This Year
- PRQR $2.87
- BNTC N/A
- Revenue Next Year
- PRQR N/A
- BNTC N/A
- P/E Ratio
- PRQR N/A
- BNTC N/A
- Revenue Growth
- PRQR 85.91
- BNTC N/A
- 52 Week Low
- PRQR $1.07
- BNTC $5.74
- 52 Week High
- PRQR $4.62
- BNTC $16.90
- Technical
- Relative Strength Index (RSI)
- PRQR 56.89
- BNTC 50.54
- Support Level
- PRQR $1.47
- BNTC $13.48
- Resistance Level
- PRQR $1.82
- BNTC $14.20
- Average True Range (ATR)
- PRQR 0.13
- BNTC 0.89
- MACD
- PRQR 0.01
- BNTC -0.02
- Stochastic Oscillator
- PRQR 44.95
- BNTC 40.27
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.